Learn More-External Link
Trending at Lumira Ventures
Archemix Signs Aptamer Therapeutics Agreement with Lilly
Archemix also strengthens IP portfolio through patent license October 20, 2008 08:30 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, announced today that it has signed an agreement with …
Personal Cell Analysis System helps battle global AIDS pandemic – Guava Technologies
Learn More-External Link
Cardiac Dimensions(R) Inc. Receives ISO 13485:2003 Certification
Learn More-External Link
Argos Therapeutics Publishes Approach to Improving Dendritic Cell-Based Immunotherapy
Learn More-External Link
Cardiac Dimensions® Inc. announces Key Personnel Changes
Learn More-External Link
Guava developing bead-based detection
Learn More-External Link
Guava Technologies signs agreement with Hudson Control Group
Learn More-External Link
San Francisco Bay Area Cell Analysis Company Announces New Multiplexing Technology for Cytokines
Learn More-External Link
Archemix Expands Collaboration with Ribomic for Rights to Develop Aptamer Therapeutics for Multiple Drug Targets
August 08, 2008 09:00 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Archemix Corp., a biotechnology company focused on discovering, developing and commercializing aptamer therapeutics, announced today that it granted Ribomic Inc., a worldwide, non-exclusive license to certain of its intellectual property …